Get the Stockscreener App
5.39
2.06%
-0.05
Acrivon Therapeutics Inc stock is traded at $5.39, with a volume of 4,405.
It is down -2.06% in the last 24 hours and down -5.77% over the past month.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$5.34
Open:
$5.34
24h Volume:
4,405
Relative Volume:
0.08
Market Cap:
$166.27M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-1.9388
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
-5.60%
1M Performance:
-5.77%
6M Performance:
-43.58%
1Y Performance:
+17.00%
1-Day Range:
$5.25
$5.5899
1-Week Range:
$5.25
$5.96
52-Week Range:
$4.31
$11.90
Acrivon Therapeutics Inc Stock (ACRV) Company Profile
Name
Acrivon Therapeutics Inc
Sector
Industry
Phone
617-207-8979
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Compare ACRV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ACRV
Acrivon Therapeutics Inc
|
5.3843 | 166.27M | 0 | -69.00M | -55.26M | -2.78 |
|
VRTX
Vertex Pharmaceuticals Inc
|
475.44 | 121.85B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
696.36 | 76.83B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
616.37 | 37.96B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.03 | 30.69B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beone Medicines Ltd Adr
|
267.79 | 29.71B | 3.32B | -860.46M | -1.04B | -8.32 |
Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | KeyBanc Capital Markets | Overweight |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Apr-29-24 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Mar-01-24 | Initiated | JMP Securities | Mkt Outperform |
| Dec-15-23 | Resumed | Jefferies | Buy |
| Oct-05-23 | Initiated | Maxim Group | Buy |
| Jun-02-23 | Initiated | Oppenheimer | Outperform |
| May-08-23 | Initiated | BMO Capital Markets | Outperform |
| Apr-27-23 | Initiated | Ladenburg Thalmann | Buy |
| Apr-20-23 | Initiated | H.C. Wainwright | Buy |
| Dec-12-22 | Initiated | Cowen | Outperform |
| Dec-12-22 | Initiated | Jefferies | Buy |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
View All
Acrivon Therapeutics Inc Stock (ACRV) Latest News
When (ACRV) Moves Investors should Listen - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Update - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average Target Price from Analysts - Defense World
We're Hopeful That Acrivon Therapeutics (NASDAQ:ACRV) Will Use Its Cash Wisely - Yahoo Finance
(ACRV) Trading Signals - Stock Traders Daily
Brokers Set Expectations for ACRV FY2024 Earnings - MarketBeat
FDA grants breakthrough designation for Acrivon’s endometrial cancer assay - MSN
Acrivon Therapeutics Inc (ACRV) Stock: A Year of Highs and Lows in the Market - The InvestChronicle
Acrivon Therapeutics announces FDA granted BDD for ACR-368 - Yahoo Finance
Research Analysts Offer Predictions for ACRV FY2024 Earnings - Defense World
The -10.05% Simple Moving Average of Acrivon Therapeutics Inc’s (ACRV) Stock in the Past 200 Days - The News Heater
Acrivon Therapeutics (ACRV): AI-Powered Precision Oncology Gets FDA Breakthrough Status - Insider Monkey
Acrivon Therapeutics Announces FDA has Granted Breakthrough - GlobeNewswire
ACR-368 OncoSignature assay gains FDA breakthrough status - MSN
12 AI News and Ratings Investors are Keeping Their Eye On - Insider Monkey
Acrivon Therapeutics gets FDA breakthrough device designation for its oncosignature assay for endometrial cancer - MSN
Acrivon Therapeutics Says FDA Grants its ACR-368 OncoSignature Assay Breakthrough Device Designation - Marketscreener.com
Acrivon Therapeutics, Inc. Announces FDA Grants Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - Marketscreener.com
Acrivon Therapeutics Gets FDA Breakthrough Device Designation for Cancer Identification - Marketscreener.com
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 OncoSignature Assay for Endometrial Cancer - The Manila Times
ACR-368 OncoSignature assay gains FDA breakthrough status By Investing.com - Investing.com UK
Acrivon Therapeutics Announces FDA has Granted Breakthrough Device Designation for ACR-368 - The Bakersfield Californian
Acrivon's AI-Powered Cancer Test Achieves 62.5% Response Rate, Earns FDA Breakthrough Status - StockTitan
Acrivon Therapeutics (NASDAQ:ACRV) Coverage Initiated at KeyCorp - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Analysts at Cantor Fitzgerald - MarketBeat
Acrivon Therapeutics (NASDAQ:ACRV) Research Coverage Started at Cantor Fitzgerald - Defense World
Acrivon Therapeutics (NASDAQ:ACRV) Earns Overweight Rating from Analysts at KeyCorp - Defense World
Head-To-Head Analysis: Jazz Pharmaceuticals (NASDAQ:JAZZ) & Acrivon Therapeutics (NASDAQ:ACRV) - Defense World
Short Interest in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Rises By 6.3% - MarketBeat
JPMorgan Chase & Co. Has $238,000 Position in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Cantor Fitzgerald sets Acrivon stock to Overweight on AP3 platform - MSN
Cantor Fitzgerald Initiates Acrivon Therapeutics at Overweight -January 31, 2025 at 08:14 am EST - Marketscreener.com
(ACRV) Trading Report - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Average PT from Brokerages - Defense World
Barclays PLC Raises Stock Holdings in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 6.3% in December - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
(ACRV) On The My Stocks Page - Stock Traders Daily
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Sees Significant Growth in Short Interest - MarketBeat
Geode Capital Management LLC Has $2.12 Million Stake in Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Investment Report - Stock Traders Daily
Barclays PLC Acquires 11,273 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
State Street Corp Acquires 47,233 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.67 Consensus PT from Brokerages - Defense World
Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Charles Schwab Investment Management Inc. Sells 27,705 Shares of Acrivon Therapeutics, Inc. (NASDAQ:ACRV) - Defense World
(ACRV) Long Term Investment Analysis - Stock Traders Daily
Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal phase - Investing.com
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis - Seeking Alpha
Acrivon Therapeutics Inc Stock (ACRV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Acrivon Therapeutics Inc Stock (ACRV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| PERCEPTIVE ADVISORS LLC | 10% Owner |
Apr 11 '24 |
Buy |
8.50 |
2,353,000 |
20,000,500 |
5,360,858 |
1.31%
0.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):